Ramsay Stattman Vela & Price Inc. Sells 1,436 Shares of Danaher Co. (NYSE:DHR)

Ramsay Stattman Vela & Price Inc. lessened its position in shares of Danaher Co. (NYSE:DHR) by 2.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 68,552 shares of the conglomerate’s stock after selling 1,436 shares during the quarter. Danaher comprises about 3.5% of Ramsay Stattman Vela & Price Inc.’s investment portfolio, making the stock its 6th largest position. Ramsay Stattman Vela & Price Inc.’s holdings in Danaher were worth $19,059,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in DHR. CarsonAllaria Wealth Management Ltd. acquired a new position in Danaher in the second quarter valued at about $25,000. nVerses Capital LLC acquired a new stake in shares of Danaher during the second quarter worth about $25,000. Redmont Wealth Advisors LLC acquired a new stake in shares of Danaher during the first quarter worth about $30,000. MFA Wealth Advisors LLC acquired a new stake in shares of Danaher during the second quarter worth about $51,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Danaher during the second quarter worth about $51,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of a number of research analyst reports. Robert W. Baird dropped their price target on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Evercore ISI raised their price target on Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. KeyCorp increased their price objective on Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a report on Wednesday, October 23rd. The Goldman Sachs Group raised their price target on Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Finally, TD Cowen lifted their price target on Danaher from $310.00 to $315.00 and gave the stock a “buy” rating in a report on Wednesday, October 23rd. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $287.28.

Insiders Place Their Bets

In other Danaher news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. In other news, Director Linda Filler sold 3,928 shares of Danaher stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $279.50, for a total value of $1,097,876.00. Following the completion of the transaction, the director now directly owns 41,149 shares in the company, valued at approximately $11,501,145.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,059 shares of company stock valued at $8,400,897 over the last ninety days. 11.10% of the stock is currently owned by insiders.

Danaher Trading Down 0.6 %

NYSE DHR traded down $1.38 during trading hours on Tuesday, hitting $242.74. 1,232,854 shares of the company’s stock were exchanged, compared to its average volume of 2,732,435. The stock has a 50-day simple moving average of $268.98 and a 200 day simple moving average of $260.53. The firm has a market cap of $179.79 billion, a price-to-earnings ratio of 41.38, a PEG ratio of 4.49 and a beta of 0.83. The company has a current ratio of 1.43, a quick ratio of 1.04 and a debt-to-equity ratio of 0.33. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.59 billion. During the same quarter last year, the company earned $2.02 earnings per share. The company’s revenue for the quarter was up 3.1% on a year-over-year basis. On average, equities analysts forecast that Danaher Co. will post 7.59 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, October 25th. Shareholders of record on Friday, September 27th were given a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.